Case report

Immunohistochemical investigations and introduction of new therapeutic strategies in scleromyxoedema: Case report

Frank Breuckmann*, Marcus Freitag, Sebastian Rotterdam, Markus Stuecker, Peter Altmeyer and Alexander Kreuter

Address: Department of Dermatology, Ruhr-University Bochum, Gudrunstrasse 56, D-44791 Bochum, Germany

Email: Frank Breuckmann* - Frank.Breuckmann@ruhr-uni-bochum.de; Marcus Freitag - M.Freitag@derma.de; Sebastian Rotterdam - S.Rotterdam@derma.de; Markus Stuecker - M.Stuecker@derma.de; Peter Altmeyer - P.Altmeyer@derma.de; Alexander Kreuter - A.Kreuter@derma.de

* Corresponding author

Abstract

**Background:** Scleromyxoedema is a rare chronic skin disease of obscure origin, which may often be associated with severe internal co-morbidity. Even though different casuistic treatment modalities have been described, to date, curing still seems to be impossible.

**Case presentation:** We report a 44-year-old Caucasian female presenting with remarkable circumscribed, erythematous to skin-coloured, indurated skin eruptions at the forehead, arms, shoulders, legs and the gluteal region. Routine histology and Alcian blue labelling confirmed a massive deposition of acid mucopolysaccharides. Immunohistochemical investigations revealed proliferating fibroblasts and a discrete lymphocytic infiltration as well as increased dermal expression of MIB-1+ and anti-mastcell-tryptase+ cells. Bone marrow biopsies confirmed a monoclonal gammopathy of undetermined significance without morphological characteristics of plasmocytoma; immunofixation unveiled the presence of IgG-kappa paraproteins.

**Conclusions:** Taking all data into account, our patient exhibited a complex form of lichen myxoedematous, which could most likely be linked a variant of scleromyxoedema. Experimental treatment with methotrexate resulted in a stabilisation of clinical symptoms but no improvement after five months of therapy. A subsequent therapeutic attempt by the use of medium-dose ultraviolet A1 cold-light photomonotherapy led to a further stabilisation of clinical symptoms, but could not induce a sustained amelioration of skin condition.

**Background**

Lichen myxoedematous (LM) represents a rare chronic skin disorder of unknown aetiology, which may often be accompanied by severe internal co-morbidity such as haematological involvement including paraproteinaemia, neurologic syndromes, gastrointestinal complications or cardiac abnormalities [1-4]. Clinically and histologically, LM is characterised by papular eruptions caused by an extensive dermal deposition of glycosaminoglycans [5]. Scleromyxoedema (SCL) is a variant of LM exhibiting erythematous, sclerotic and stiffed lesions beside lichenoid papules with only little tendency of spontaneous remission [6,7]. Even though various experimental treatment
modalities have been described, to date, curing of SCL is still not possible.

The oncoming case presentation focuses on a progressive variant of SCL as referred to clinical, immunohistochemical and laboratory investigations, followed by low-dose methotrexate (MTX) and subsequent medium-dose ultraviolet A1 (UVA1) cold-light treatment.

**Case presentation**

We report a 44-year-old Caucasian woman who initially presented in 2003 with a multitude of progressive lichenoid 2–4 mm papules starting two years ago, particularly marked on the forehead right above both eyebrows, on the dorsal aspects of the forearms, shoulders, legs as well as on the gluteal region, accompanied by severe pruritus (Fig. 1). Clinically, the papules were judged as discrete, circumscribed, erythematous to skin-coloured, firm skin eruptions associated with an induration and stiffening of the affected lesions. Furthermore, the patient complained about a progressive thickening of the glabella. Even though we cannot ensure continuous clinical deterioration, at the time of the initiation of therapy, there was no hint for a beginning stabilisation or even improvement of symptoms. Otherwise, she felt healthy and well. The general examination was without pathological findings. Neither a topical nor a systemic therapy was yet applied.

Skin biopsies were taken from the left forearm/wrist, both legs and the left shoulder. Routine histological examination including haematoxylin-eosin, PAS labelling and Alcian blue staining revealed marked mucinous deposition within the upper and mid dermis beside an increased appearance of fibroblasts, collagen bundles and a discrete inflammatory infiltration.

Additionally, immunohistochemical investigations were performed in order to enumerate CD4+ (T helper cells), CD68+ (macrophages), anti-mastcell-tryptase+ (mastcells), decorin+ (collagen fibril stability protein), MIB-1+
(Ki-67+ proliferating cells), CD20+ (B lymphocytes), and FGF-R+ (fibroblast growth factor receptor bearing cells) cells taking consecutive sections (Table 1). A punch skin biopsy measuring 3 mm in diameter was taken from affected skin of the right forearm. 5 µm paraffin-embedded sections were cut, mounted on slides and routinely preserved. Prior to the single immunolabelling, different pretreatments were performed for antigen retrieval (Table 1). The alkaline phosphatase anti-alkaline phosphatase (APAAP) technique using the labelled streptavidin-biotin (LSAB) method was used to enumerate immunopositive cells at an individual dilution (Table 1) taking consecutive sections. The alkaline phosphatase fast red detection kit utilised a biotinylated secondary antibody that binds to the primary antibody. This step was followed by the addition of a streptavidin enzyme conjugate binding to the biotin present on the secondary antibody. Afterwards the specific antibody-secondary-antibody-streptavidin-enzyme-complex was detected using a precipitating enzyme reaction product. Each step was incubated for a precise time and temperature. The alkaline phosphatase was used as enzyme; the chromogene fast red could be visualised. Cells were evaluated semiquantitatively (absent (-), rare (o), moderate (+), frequent (++)) directly below the dermoepidermal junction. Immunopositive cells were evaluated ‘blind’ separately in two view fields in a row (0.25 mm × 0.25 mm each) directly below the dermoepidermal junction resulting in a length of 0.25 mm and 0.50 mm in depth. In order to avoid a sampling error, a number of sections were randomly reevaluated by a second observer. In case of a significant difference, the sections had to be recounted by both observers. In brief, immunolabelling revealed occasional perivascular CD4+ and CD20+ lymphocytes located in the papillary dermis and a high number of anti-mastcell-tryptase+ cells within the subepithelial perivascular infiltrate revealing a continuous decrease with increasing depth (Fig. 2). Simultaneously, an increased dermal expression of MIB-1+ cells (Fig. 3), morphologically predominantly fibroblasts, within the upper and mid dermis and sporadic FGF-R+ cells in an unspecific distribution could be detected. CD68 immunohistochemistry and intradermal decorin levels did not alter remarkably as compared to healthy controls (data not shown). Exact results of all immunohistochemical stainings are detailed in Table 2.

Complete laboratory measurements unveiled the following pathological results: leucocytes 10870 µL\(^{-1}\), lymphocytes 13.2%, IgG 2000 mg/dl. There was no increase in B cell count. Immunoelectrophoresis disclosed albumin 51.4%, alpha-2 globuline 10.5%, gamma globuline 22.9%. Cranial x-ray, x-ray of the thorax, ultrasound of the abdominal organs, electrocardiography and urinary investigations were unremarkable. Blood smear cytological evaluation revealed beginning qualitative but still no quantitative changes as defined by leukocytic aberrations pointing towards a leftward shift. Serum immunofixation demonstrated an IgG-kappa paraproteinaemia. No elevation of the IgG-lambda paraprotein was assessed. Bone marrow biopsies displaying reactive lymphoid infiltration including minimal extension of plasma cells with monoclonal immunoglobuline production provided evidence for monoclonal gammopathy of undetermined significance (MGUS) without distinct morphological characteristics of a plasmocytic plasmocytoma or plasmoblasts.

Initially, 20 MHz ultrasound scanning producing cross section images of the skin was established in order to measure both structure and thickness of the skin at the dorsal aspects of the left wrist and the right forearm. The total thickness of the skin was measured from the entrance echo to the border between the dermis and the subcutaneous tissue. A cutaneous diameter of 2291 µm at the left wrist (lesional skin) and of 1106 µm at the right forearm (non-lesional skin) could be assessed.

In our unit, an experimental treatment modality using oral MTX 12.5 mg once per week followed by a subsequent folic acid application on the following day for a 6-

| Antibody | Source | Pretreatment* | Dilution | Incubation time |
|----------|--------|---------------|----------|----------------|
| CD4      | Novocastra Loxo, Dossenheim, Germany | H          | 1:60     | 30 min         |
| CD68     | Dako, Hamburg, Germany | P          | 1:25     | 30 min         |
| Tryptase | Dako, Hamburg, Germany | P          | 1:400    | 28 min         |
| MIB-1    | Dako, Hamburg, Germany | H          | 1:10     | 32 min         |
| FGF-R    | Oncogene Research, San Diego, USA | N          | 1:10     | 30 min         |
| Decorin  | Oncogene Research, San Diego, USA | N          | 1:10     | 30 min         |
| CD20     | Novocastra Loxo, Dossenheim, Germany | H          | 1:50     | 30 min         |

* N = none, P = protease digestion, H = heat (microwave-3-step-technique)
Figure 2
Immunohistochemistry unveiling sporadic lymphocytes beside a high number of anti-mastcell-tryptase$^+$ cells within the subepi-
thelial perivascular infiltrate.
Mucinous deposition of the upper and mid-dermis accompanied by an elevated occurrence of MIB-1+ dermal fibroblasts.

Figure 3
Mucinous deposition of the upper and mid-dermis accompanied by an elevated occurrence of MIB-1+ dermal fibroblasts.
months-period was subsequently initiated. MTX was well tolerated by our patient. After the first three months, the continuous progress of skin lesions during the last two years could be stopped and our patient experienced subjectively an improvement and objectively a stable clinical outcome without new lesions. Subjective impression of amelioration could not be confirmed by means of ultrasound measurement. Within the following two months, no further improvement could be evaluated, whereas no further progression such as formation of new lesions or increase of stiffness could be observed. Due to the unsatisfying clinical results and declining acceptance by our patient, MTX treatment was stopped and a subsequent therapeutic attempt with medium-dose UVA1 cold-light phototherapy was initiated. Irradiation consisting of 50 J/cm² single-dose UVA1 (CL 300000 liquid, Photomed, Hamburg, Germany) was performed four times a week for three weeks followed by two times a week for further two weeks resulting in a cumulative dose of 800 J/cm² after five weeks. Meanwhile, the skin status again remained stable, whereas no improvement could be observed. Therefore, our patient broke up phototherapy. To date, skin condition has slightly worsened without any current treatment modality.

Conclusions

The population prevalence of SCL is known to be extremely low. Skin lesions are characterised by an increased deposition of acid mucopolysaccharides within the papillary and upper reticular dermis [8]. Even today, aetiology and pathogenesis remain hypothetic. Aberrant dermal deposition of monoclonal paraproteins predominantly of the IgG subtype combined with elevated IgG serum levels indirectly stimulating fibroblast activity are frequently found in LM patients [9-11]. Nevertheless, fibromucinous lesions of LM without the presence of paraprotein accumulations have also been described [12].

Beside typical skin eruptions, LM might also be associated with severe internal and neurological abnormalities such as cardiac irregularities, paralysis, hemiparesis or even progress to coma [3,4,13]. Despite sporadic case reports introducing new therapeutic strategies in LM and SCL, common treatment modalities are still disappointing and unsatisfactory. Topical treatment including hyaluronidase and triamcinolone as well as systemic efforts by the use of corticosteroids, cyclophosphamide, electron-beam therapy, hydroxychloroquine, PUVA, extracorporeal photopheresis, plasmapheresis or high-dose intravenous immunoglobulin partly displayed only limited success in individual patients [12,14-20].

In our patient, Alcian blue staining disclosed a remarkable deposition of mucinous material within the upper dermal layers combined with an increased appearance of proliferating MIB-1+ and occasional FGF-R+ fibroblasts in immunohistochemistry. Ki-67 (MIB-1) and fibroblast growth factors are involved in a variety of mitogen and proliferative activities [21]. Thus, the enhanced appearance of positive cells might represent an increased overall activation probably resulting in an aberrant release of mucopolysaccharides. Decorin contributes to the collagen fibril stability and high levels of decorin seem to be closely linked to dermal fibrotic stages as known from systemic sclerosis [22]. Here, an increased intradermal decorin expression could not be demonstrated. Simultaneously, in our patient the mucinous deposition was accompanied by a decreased presence of collagenous bundles. Interestingly, immunohistochemistry also revealed a number of CD4+ and CD20+ dermal inflammatory lymphocytes as well as anti-human mast cell tryptase+ cells, which may profoundly contribute to mucinosis formation [23]. Unfortunately, we were not able to provide a longitudinal analysis of the different stainings due to missing consent of the patient to perform additional experimental biopsies within the course of therapy.

By considering clinical appearance, laboratory findings, immunofixation, bone marrow biopsy and histological evaluation, our patient presumably exhibited a complex variant of SCL. Fibroblast activity was supposed to be increased reflected by a corresponding high number of MIB-1+ and FGF-R+ cells within the upper dermis beside a massive mucinous deposition.

MTX therapy is approved in the treatment of malignant lymphoma. Additionally, low-dose MTX therapy has been established as a potent regimen in the treatment of T cell
related skin diseases associated with a subsequent elevated fibroblast activation status (e.g. progressive systemic sclerosis) [24]. In our patient paraproteinaemia of the IgG-kappa class, morphological signs of MGUS, proliferating dermal fibroblasts and a discrete T cell weighted lymphocytic dermal infiltration could be verified, we first decided to start a therapeutic attempt by the use of 12.5 mg MTX weekly in order to suppress local cellular activity following the promising reports about application of the anti-metabolite melphalan and the alkylating agent cyclophosphamide in previous studies [12,14]. Follow-up examinations were performed monthly. Three months after initiation of MTX therapy, an encouraging stable clinical outcome as well as an decline of pruritus without further progression of the disease was observed. However, the 5-months-follow-up revealed no apparent improvement of skin status leading to the joint decision of breaking up MTX treatment. UVA1 phototherapy has been shown to be effective in a number of inflammatory and fibrotic skin disorders by the induction of T cell apoptosis, collagenase activity and antiproliferative pathways [25]. Therefore, we decided to initiate a second attempt by the usage of a common medium-dose UVA1 irradiation protocol. Nevertheless, our patient broke up this regimen even after a 5-weeks-period due to the absence of immediate clinical improvement and an unfavourable time/benefit ratio, while follow-up examinations during this time revealed a stop of the progress anyway.

However, in order to interrupt the clinical progression or even therapy-resistance as reflected by our case presentation and by considering the stable skin conditions following UVA1 phototherapy, we are currently discussing a new treatment protocol applying extracorporeal photochemotherapy, as proposed by Krasagakis et al. [16], in order to stabilise or even improve the present slight aggravation without any potent therapy.

**List of abbreviations**

LM: Lichen myxedematosus; SCL: Scleromyxedema; MTX: methotrexate; UVA1: ultraviolet A1; MGUS: monoclonal gammopathy of undetermined significance

**Competing interests**

None declared.

**Authors’ contributions**

F.B. participated in the design of the study, carried out the immunohistochemistry, performed the statistical analysis and drafted the manuscript. S.R. carried out 20 MHz ultrasound scanning. A.K. conceived of the study. M.F., M.S. and P.A. participated in histology, design and coordination.

All authors read and approved the final manuscript.

**References**

1. Pomann JJ, Rudner E: Scleromyxedema revisited. Int J Dermatol 2003, 42:31-35.
2. Ayala F, Balato N, Ceparano S, Castello G: Immunochemical characterization of the abnormal paraprotein in a case of scleromyxedema. Clin Exp Dermatol 1984, 9:351-357.
3. Webster GF, Matsuoka LY, Burchmore D: The association of potentially lethal neurologic syndromes with scleromyxedema (papular mucinosis). J Am Acad Dermatol 1993, 28:105-108.
4. Morris-Jones R, Staugeron RC, Walker M, Shulman DJ, Rajappan K, Leonard J, Hardman C: Lichen myxedematosus with associated cardiac abnormalities. Br J Dermatol 2001, 144:594-596.
5. Takama H, Ohashi M, Iwata H: Scleromyxedema – studies on glycosaminoglycans (authors trans). Nippon Hifuka Gakkai 1976, 7:425.
6. Rudner Ej, Mehregan A, Pinkus H: Scleromyxedema: a variant of lichen myxedematosus. Arch Dermatol 1966, 93:3-12.
7. Rongioletti F, Rebora A: Updated classification of papular mucinosis, lichen myxedematosus, and scleromyxedema. J Am Acad Dermatol 2001, 44:273-281.
8. Hill TG, Crawford JN, Rogers CC: Successful management of lichen myxedematosus. Arch Dermatol 1976, 112:67-69.
9. McCarthy JT, Osserman E, Lombardo PC, Takatsuki K: Multiple serum protein abnormalities in lichen myxedematosus. Arch Dermatol 1964, 89:446-450.
10. Howell NR, Waite A, Scott DG: Multiple serum protein abnormalities in lichen myxedematosus. Br J Dermatol 1969, 81:753-758.
11. Stucker M, Nowack U, Röchling A, Bacharach-Buhles M, el Gammal S, Panz B, Altmeyer P: Sweat gland proliferations in scleromyxedema. Arch J Dermatopath 1999, 21:259-264.
12. Howsdon SM, Horndon JH Jr, Freeman RG: Lichen myxedematosus. A dermal infiltrative disorder responsive to cyclophosphamide therapy. Arch Dermatol 1975, 111:1325-1330.
13. Rongioletti F, Hazini A, Rebora A: A normal serum globulin in lichen myxedematosus. Arch Dermatol 1964, 89:446-450.
14. Howsdon SM, Horndon JH Jr, Freeman RG: Lichen myxedematosus. A dermal infiltrative disorder responsive to cyclophosphamide therapy. Arch Dermatol 1975, 111:1325-1330.
15. Koeppel MC, Aquilina C, Terrier G, Sayag J: Electron-beam therapy in Arndt-Gottron’s scleromyxedema. Br J Dermatol 1993, 129:733-735.
16. Krasagakis K, Zouboulis CC, Owisanowski, Ramaker J, Trautmann C, Tebbe B, Orfanos CE: Remission of scleromyxedema following treatment with extracorporeal photopheresis. Br J Dermatol 1996, 135:462-466.
17. Farr PM, Ives FA: PUVA treatment of scleromyxedema. Br J Dermatol 1984, 110:347-350.
18. Adachi Y, Iba S, Horio T: Successful treatment of lichen myxedematosus with PUVA photochemotherapy. Photomed Dermatol Photoimmunol Photomed 2000, 16:229-231.
19. Terheyden P, Becker JC, Lurz C, Kahaly GJ, Brocker EB: Treatment of scleromyxedema with hydroxychloroquine. JDDG 2003, 1:30-35.
20. Kulczycki A, Nelson M, Eisen A, Heffeman M: Scleromyxedema: treatment of cutaneous and systemic manifestations with high-dose intravenous immunoglobulin. J Br Dermatol 2003, 149:1276-1281.
21. Bergers WH, Maciag T: The heparin-binding (fibroblast) growth factor family of proteins. Ann Rev Biochem 1989, 58:575-606.
22. Sawada H, Isogai Z, Morita A: Altered decorin expression of systemic sclerosis by UVA1 (340–400 nm) phototherapy: Immunochemical analysis of 3 cases. BMC Dermatol 2003, 3:2.
23. Abd El-Aaal H, Salem SZ, Salem A: Lichen myxedematosus: histochmical study. Dermatologica 1981, 162:273-276.
24. Jablonska S, Blassczyk M: New treatments in scleroderma: dermatologic perspective. JEADV 2002, 16:526-528.
25. Dawe RS: Ultraviolet A1 phototherapy. Br J Dermatol 2003, 148:626-637.
Pre-publication history
The pre-publication history for this paper can be accessed here:

http://www.biomedcentral.com/1471-5945/4/12/prepub